CymaBay Therapeutics will present results of its Phase 2 proof-of-concept MBX-8025 clinical trial at the Annual Meeting of the American Association for the Study of Liver Diseases Nov. 11-15 in Boston.
MBX-8025 is administered to patients orally for the treatment of primary biliary cholangitis. It is composed of peroxisome proliferator-activated receptor delta agonist that is both potent and selective.
The presentation will be called “A phase 2 proof of concept study of MBX-8025 in patients with Primary Biliary Cholangitis who are inadequate responders to ursodeoxycholic acid” and has already been published through the AASLD website.
Professor David Jones, Institute of Cellular Medicine Professor of Liver Immunology, will present the results of the trial on Nov. 15.